This study is for people who have finished one of two earlier studies and want to continue taking a medicine called pelacarsen (TQJ230). Pelacarsen is a treatment given once a month to help people with high levels of a substance called Lp(a) and a heart condition known as ASCVD (Atherosclerotic Cardiovascular Disease).
In this new study, everyone knows they are getting the medicine, unlike in the previous studies where some didn't know if they received the medicine or a placebo. The aim is to see if the medicine is safe to use for a long time.
- Participants must have completed the earlier study and agree to continue with this one.
- If someone had to stop the medicine before due to bad reactions, they can't join this extension study.
- Doctors will decide if any other health issues might make participating unsafe for someone.
It's important to talk to a doctor to understand the risks and benefits before joining. Participants will help researchers learn more about the long-term safety of pelacarsen.